Palatin Announces $10 Million Registered Direct Offering
- None.
- None.
The recent strategic move by Palatin Technologies to raise capital through the issuance of shares and warrants to institutional investors indicates a proactive approach to funding their research and development initiatives. This capital infusion, priced at $5.46 per share, is critical for a biopharmaceutical company that relies on continuous investment to drive their pipeline projects forward.
From a financial perspective, the transaction suggests a vote of confidence from institutional investors in Palatin's potential, which could signal underlying value in their melanocortin receptor system modulators. However, the dilutive effect of increasing the number of shares outstanding can potentially impact existing shareholders' value negatively in the short term. The exercise of warrants could further dilute shareholder value but also represents an additional future cash inflow if the company's stock performs well.
Investors should monitor the deployment of these funds, as efficient use could lead to advancements in their product pipeline, potentially enhancing long-term shareholder value. Conversely, any missteps in the utilization of proceeds could hinder the company's progress and impact its financial health.
The melanocortin receptor system is a critical target for therapeutic intervention, with implications for a range of medical conditions. Palatin's focus on this pathway could address unmet medical needs, presenting significant market opportunities if their drug candidates succeed in clinical trials.
Investors and stakeholders should be aware that drug development is inherently risky, with a high rate of attrition in clinical trials. The capital raised will likely support ongoing preclinical and clinical studies, which are essential steps towards regulatory approval. The successful development of their medicines could lead to substantial returns, but there is also a significant risk of loss if the drug candidates fail to prove efficacy or safety.
It is essential to evaluate the company's track record, the scientific validity of their approach and the competitive landscape. Any progress in clinical trials could positively impact the company's valuation, while setbacks could lead to volatility in the stock price.
Palatin's entry into a definitive agreement with healthcare-focused institutional investors reflects broader trends in the biopharmaceutical sector, where companies often seek to bolster their financial positions to sustain long-term projects. The chosen mechanism of a mixed offering with both common stock and warrants demonstrates a strategic approach to balance immediate funding needs with the potential for future capital.
Understanding the market dynamics, including investor sentiment, regulatory environment and competitive pressures is crucial. The role of H.C. Wainwright & Co. as the exclusive placement agent could be instrumental in navigating these aspects, ensuring the offering is in line with market conditions and investor expectations.
Market participants should consider the timing and terms of the offering, as they may reflect the company's negotiation leverage and current market appetite for biopharmaceutical investments. These factors can influence not just Palatin's financial trajectory but also provide insight into the sector's funding environment.
H.C. Wainwright & Co. is acting as exclusive placement agent for the offering.
The closing of the offering is expected to occur on or about February 1, 2024, subject to the satisfaction of customary closing conditions. The gross proceeds from the offering are expected to be approximately
The shares of common stock described above (excluding the warrants and the shares of common stock underlying the warrants) are being offered by Palatin pursuant to a shelf registration statement on Form S-3 (File No. 333-262555) that was previously filed with the Securities and Exchange Commission ("SEC") on February 7, 2022, and subsequently declared effective on September 26, 2022. The offering of shares of common stock to be issued in the registered direct offering is being offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and accompanying base prospectus relating to, and describing the terms of, the registered direct offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying base prospectus relating to the registered direct offering, when available, may also be obtained by contacting H.C. Wainwright & Co., LLC, at 430 Park Ave.,
The warrants described above will be issued in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and Regulation D promulgated thereunder and, along with the shares of common stock underlying such warrants, will not be registered under the Securities Act, or applicable state securities laws. Accordingly, the warrants and underlying shares of common stock, upon issuance, may not be offered or sold in
This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Palatin
Palatin is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at www.Palatin.com and follow Palatin on Twitter at @PalatinTech.
Forward-looking Statements
Statements in this press release that are not historical facts, including statements related to the timing and completion of the offering, the satisfaction of customary closing conditions related to the offering and the intended use of proceeds therefrom, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Forward-looking statements reflect the Company's current views with respect to future events and are based on assumptions and subject to known and unknown risks and uncertainties, which change over time, and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include, without limitation, market and other conditions, the ability of the Company to satisfy all conditions precedent to the closing of the offering; the anticipated use of proceeds from the offering; results of clinical trials; regulatory actions by the FDA and other regulatory and the need for regulatory approvals; Palatin's ability to fund development of its technology and establish and successfully complete clinical trials; the length of time and cost required to complete clinical trials and submit applications for regulatory approvals; products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies; commercial acceptance of Palatin's products; and other factors discussed in Palatin's periodic filings with the SEC. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise unless required by law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/palatin-announces-10-million-registered-direct-offering-302047600.html
SOURCE Palatin Technologies, Inc.
FAQ
What is the purchase price of Palatin Technologies, Inc.'s common stock in the offering?
How many shares of common stock are being issued and sold in the offering?
What is the exercise price of the warrants to purchase common stock in the offering?
Who is acting as the exclusive placement agent for the offering?
When will the warrants become exercisable and expire?
